Cervical cancer test kit jumps Asian cultural hurdles

SINGAPORE Mon Mar 26, 2012 5:20pm IST

Related Topics

SINGAPORE (Reuters) - A Singapore-Dutch joint venture has launched a home test kit for cervical cancer to make the process more convenient and help women, particularly in Asia, overcome fear of the traditional pap smear.

Cervical cancer, with about 500,000 new cases and 250,000 deaths each year, is the second most common cancer among women after breast cancer, the World Health Organization says.

"We are still struggling with reaching out to women for cervical cancer screening in Asia," Singapore gynecological oncologist Tay Eng Hseon said at a media briefing on Monday, citing factors such as shyness, culture, fear and lack of time.

Delphi Bioscience Asia Pte Ltd is a collaboration between Delphi Bioscience BV, a life sciences company based in the Netherlands, and its Singapore partners Tay and businessman David Tan.

The Delphi screener, with a cylindrical shape and round tip, can be inserted to the top of the cervix by the user to collect cells with a sterile, saline liquid. This is then used to test for high-risk Human Papilloma Virus (HPV), which could cause cervical cancer.

In a pap smear, cells are scraped from the opening of the cervix with a speculum and then examined under a microscope.

The recommended retail price for the screener is S$79.90 ($63), including the laboratory test. This compares with S$30-40 for a pap smear in a clinic and more than S$100 for an HPV test, Tay said.

Delphi expects the screener to be available at about 100 family physician clinics in Singapore over the next three months and hopes to use the Southeast Asian city-state as a regional launchpad.

Tan, executive managing director (commercial) at Delphi Bioscience Asia, said its Indonesian distributor has committed to 1.5 million units over the next 12 months and Malaysia is next in the company's sights.

But China, the world's second-largest economy, poses significant regulatory hurdles, Tan said.

"China is not on our immediate radar for obvious reasons," he said. "Regulatory approvals take a long time and they are very complicated." ($1 = 1.2626 Singapore dollars)

(Reporting by Eveline Danubrata; Editing by John O'Callaghan)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

REUTERS EXCLUSIVE

HEALTH SHOWCASE

Walk for Fitness

Walk for Fitness

Walking is the superfood of fitness, experts say.  Full Article 

Ebola Outbreak

Ebola Outbreak

Bill Gates warns Ebola could spread beyond West Africa.  Full Article | Related Story 

Birth Control

Birth Control

Long-acting reversible contraceptives best for teens: pediatricians.  Full Article 

Trial Goal Met

Trial Goal Met

Seattle Genetics and Takeda's cancer drug meets main trial goal.  Full Article 

Childhood Obesity

Childhood Obesity

Antibiotics in infancy may be linked to childhood obesity: study.  Full Article 

MERS Update

MERS Update

Austria reports first MERS case in Saudi national: media.  Full Article 

Sinusitis Drug

Sinusitis Drug

Sanofi-Regeneron drug has positive trial results in chronic sinusitis.  Full Article